IN8bio Strengthens R&D Leadership with γδ T Cell Expert — IN8bio, Inc.

Event summary

IN8bio appoints Oxana Polyakova, Ph.D., as Senior Vice President of Research & Development on September 9, 2026.
Dr. Polyakova brings 20 years of experience in γδ T cell biology and T cell engager (TCE) development.
She previously served as Chief Scientific Officer at LAVA Therapeutics and LIfT Biosciences.
Dr. Polyakova will lead IN8bio’s R&D strategy, focusing on accelerating T cell engager programs.
IN8bio’s pipeline includes INB-600 (γδ TCE platform), INB-100 (allogeneic γδ T cell therapy), and INB-200/400 (autologous γδ T cell therapy).

The big picture

IN8bio’s appointment of Dr. Polyakova underscores its commitment to advancing γδ T cell therapies, a niche but growing segment of the biopharmaceutical industry. Her extensive background in TCE development positions IN8bio to compete more effectively in the immuno-oncology space, where targeted cell therapies are gaining traction. The move also signals IN8bio’s intent to broaden its therapeutic applications beyond oncology into autoimmune diseases, a strategic pivot that could open new revenue streams.

What we're watching

Pipeline Acceleration: How Dr. Polyakova’s expertise will impact the pace of IN8bio’s TCE platform development.
Strategic Expansion: Whether IN8bio can successfully expand its γδ T cell platform into new autoimmune and oncology indications.
Industry Leadership: The extent to which IN8bio can solidify its position as a leader in γδ T cell therapies.